TeleRare Health Introduces Virtual Genetic Consults for Patients

TeleRare Health Launches Virtual Genomic Consultation Service
TeleRare Health has proudly announced the commencement of its Virtual Genomic Consults, providing immediate support for patients facing challenges with rare diseases and genetic conditions. This innovative initiative is particularly beneficial for those navigating the complex world of rare and genetic disorders in Minnesota.
Understanding Rare Diseases and Their Impact
In the context of healthcare in the United States, a disease is classified as rare if it affects fewer than 200,000 individuals. The National Institutes of Health (NIH) estimates that over 30 million Americans are afflicted with approximately 10,000 different rare diseases. Moreover, many of these conditions are genetic, thus emphasizing the need for expert guidance.
Benefits of TeleRare Health's Virtual Consults
The Virtual Genomic Consult Service offered by TeleRare Health allows patients to obtain a swift and precise diagnosis, along with genomic-informed care tailored to their specific needs. This service caters to both pediatric and adult patients, acknowledging that rare diseases can often entail long and arduous diagnostic journeys.
Personalized Treatment Options
Patti Engel, President of TeleRare Health, highlighted the importance of individualized treatment options. Many patients, along with their families, face daunting treatment choices that can often feel overwhelming. Our Virtual Genomic Consult Service ensures that each participant receives customized, evidence-based treatment alternatives.
Convenience and Accessibility
TeleRare Health’s appointments can be scheduled virtually, making it easier for patients to access the specialist care they require without the burden of travel. This streamlined process allows for consultations that can potentially occur within the same week, ensuring critical care when it's most needed.
Understanding Genetic Testing and Costs
Genetic testing is central to the care of many rare disease patients, as over 80% of these conditions have a genetic basis. This makes it crucial for patients to understand which genetic assays might be necessary. The TeleRare Health service assists patients in evaluating their needs, including the anticipated copay costs for optimal tests like Whole Exome Sequencing (WES).
Focus on Outcomes
Austin Letcher, Chief Operations Officer, provided insight into the treatment landscape for rare disease patients, outlining that many may have access to FDA-approved treatments, while others might require involvement in clinical trials. TeleRare Health is dedicated to navigating this complex triad of options, evaluating the most effective paths for better health outcomes for each patient.
A Vision for the Future
TeleRare Health aims to stand out as the leading provider of virtual care for rare and genomic diseases, not only in Minnesota but in the wider national landscape. The organization envisions a future where every patient has access to advanced diagnostics, cutting-edge treatments, and expert specialists.
Commitment to Advancing Healthcare
TeleRare Health is devoted to helping individuals acquire the critical genetic testing they require. The organization aspires to enable patients to benefit fully from the ongoing advancements in artificial intelligence and genomics. Continuous monitoring of new clinical variant information enables patients to stay informed about their conditions.
Recognition and Awards
Recently, TeleRare Health received the Early-Stage Innovation award at a competition that promotes pediatric innovations within digital health. This esteemed recognition underscores the organization's commitment to enhancing healthcare for pediatric patients through innovative technological solutions.
About TeleRare Health
TeleRare Health operates as a National Virtual Clinic, actively transforming the healthcare landscape via virtual genetics. Our core objectives focus on significantly reducing the Time to Diagnosis (TTD) and Time to Treatment Initiation (TTI) for rare disease patients, managing care in a manner that is not only effective but also highly convenient. For more information, visit our website.
Frequently Asked Questions
What services does TeleRare Health provide?
TeleRare Health offers Virtual Genomic Consults for both pediatric and adult patients, focusing on rare and genetic diseases.
How can patients schedule an appointment?
Patients can conveniently schedule virtual appointments, often potentially within the same week, allowing for timely care.
Why are genetic tests important for rare diseases?
Genetic tests help identify the underlying causes of rare diseases, guiding effective treatment decisions.
What is Whole Exome Sequencing (WES)?
WES is a genetic testing method that analyzes the coding regions of genes, which is critical for diagnosing many rare conditions.
Is TeleRare Health recognized for its services?
Yes, TeleRare Health was awarded the Early-Stage Innovation award for their contributions to pediatric digital health.
About The Author
Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.